Up-regulation of CD163 expression in subpopulations of blood monocytes after kidney allograft transplantation.

M2 macrophages expressing CD163 are known to suppress immune responses but have been also found in biopsies of patients with chronic kidney allograft injury associated with interstitial fibrosis. The aim of our study was to evaluate the expression of CD163 in blood monocytes, precursors of tissue macrophages, in kidney allograft recipients with uncomplicated outcome (n=94) compared with those developing acute rejection (n=44). Blood samples were collected before the transplantation and at 1 week, 1 month and 1 year. The expression of CD163 increased during the first week after the transplantation not only in classical (CD14+CD16-) but also in intermediate (CD14+CD16+) and nonclassical (CD14lowCD16+) monocytes in all patients regardless of their rejection status. In patients developing acute rejection, higher pre-transplant expression of CD163 on blood monocytes was found. In vitro experiments confirmed strong induction of membrane CD163 on monocytes together with CD206 (an alternative marker of M2 macrophages) in response to IL-10. We assume from our data that dramatic upregulation of CD163 by peripheral blood monocytes may have a pathophysiological role in early phases after kidney allograft transplantation and high pre-transplant expression of CD163 on blood monocytes might be involved in events leading to acute rejection.

[1]  Dave Singh,et al.  Effects of Corticosteroids on COPD Lung Macrophage Phenotype and Function. , 2020, Clinical science.

[2]  O. Viklicky,et al.  Molecular Assessment of Kidney Allografts: Are We Closer to a Daily Routine? , 2020, Physiological research.

[3]  M. Naesens,et al.  The Causes of Kidney Allograft Failure: More Than Alloimmunity. A Viewpoint Article. , 2020 .

[4]  M. Naesens,et al.  The causes of kidney allograft failure: more than allo-immunity. A viewpoint paper. , 2020, Transplantation.

[5]  I. Stříž,et al.  Adaptive innate immunity or innate adaptive immunity? , 2019, Clinical science.

[6]  T. Yeo,et al.  A Novel, Five-Marker Alternative to CD16–CD14 Gating to Identify the Three Human Monocyte Subsets , 2019, Front. Immunol..

[7]  J. T. Afshari,et al.  Macrophage plasticity, polarization, and function in health and disease , 2018, Journal of cellular physiology.

[8]  Yanfang Jiang,et al.  Circulating CD14+CD163+CD206+ M2 Monocytes Are Increased in Patients with Early Stage of Idiopathic Membranous Nephropathy , 2018, Mediators of inflammation.

[9]  Y. Oda,et al.  CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine Sarcoma. , 2018, Cancer research.

[10]  K. Huh,et al.  Clinical Significance of Macrophage Polarization in Antibody-Mediated Rejection of Renal Allograft. , 2018, Transplantation proceedings.

[11]  S. Sarin,et al.  Donor CD163 and nestin‐positive cells predict graft function in living donor liver transplant , 2018, Clinical transplantation.

[12]  M. Stegall,et al.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  E. Latulippe,et al.  IL‐6 production by monocytes is associated with graft function decline in patients with borderline changes suspicious for acute T‐cell‐mediated rejection: a pilot study , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[14]  Andreas Radbruch,et al.  Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint , 2017, Annals of the rheumatic diseases.

[15]  D. Nieboer,et al.  Pretransplant Numbers of CD16+ Monocytes as a Novel Biomarker to Predict Acute Rejection After Kidney Transplantation: A Pilot Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  K. Caliskan,et al.  CD16+ Monocytes and Skewed Macrophage Polarization Towards M2 Type Hallmark Heart Transplant Acute Cellular Rejection , 2017 .

[17]  J. Kautzner,et al.  Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. , 2017, Physiological research.

[18]  M. Haluzík,et al.  An alternatively activated macrophage marker CD163 in severely obese patients: the influence of very low-calorie diet and bariatric surgery. , 2017, Physiological research.

[19]  Z. Al-Aly,et al.  Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[20]  K. Caliskan,et al.  CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection , 2017, Front. Immunol..

[21]  Xiao-bin Cui,et al.  CD163 as a marker of M2 macrophage, contribute to predict aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma , 2017, Oncotarget.

[22]  M. Netea,et al.  Predominant Tubular Interleukin-18 Expression in Polyomavirus-Associated Nephropathy , 2016, Transplantation.

[23]  A. Finn,et al.  CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury , 2015, Nature Communications.

[24]  H. Okamoto,et al.  Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients. , 2015, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[25]  Seungbong Han,et al.  Interpreting CD56+ and CD163+ Infiltrates in Early versus Late Renal Transplant Biopsies , 2015, American Journal of Nephrology.

[26]  Toshiaki Suzuki,et al.  Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury , 2015, Pediatric Nephrology.

[27]  D. Ingram,et al.  Clinical significance of monocyte heterogeneity , 2015, Clinical and Translational Medicine.

[28]  H. Møller,et al.  Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti‐TNF‐α Antibody Treatment in Active Inflammatory Bowel Disease , 2014, Scandinavian journal of immunology.

[29]  R. Xavier,et al.  Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity , 2014, Science.

[30]  V. Lánská,et al.  CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation , 2014, BMC Immunology.

[31]  E. Ars,et al.  Monocyte implication in renal allograft dysfunction , 2014, Clinical and experimental immunology.

[32]  S. Moestrup,et al.  Structural Basis for Inflammation-driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-α in Macrophages* , 2013, The Journal of Biological Chemistry.

[33]  Wing-Cheong Wong,et al.  Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. , 2011, Blood.

[34]  S. Moestrup,et al.  Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. , 2011, Immunobiology.

[35]  Silvano Sozzani,et al.  Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.

[36]  N. Van Rooijen,et al.  An Innate Response to Allogeneic Nonself Mediated by Monocytes1 , 2009, The Journal of Immunology.

[37]  J. Egido,et al.  The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. , 2009, Atherosclerosis.

[38]  T. K. van den Berg,et al.  The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. , 2009, Blood.

[39]  A. Kirk,et al.  Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  S. Moestrup,et al.  CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. , 2006, Immunobiology.

[41]  T. K. van den Berg,et al.  The macrophage scavenger receptor CD163. , 2005, Immunobiology.

[42]  T. Langmann,et al.  The Scavenger Receptor CD163: Regulation, Promoter Structure and Genomic Organization , 2000, Pathobiology.

[43]  I. Stříž,et al.  The phenotype of alveolar macrophages and its correlation with immune cells in bronchoalveolar lavage. , 1993, The European respiratory journal.

[44]  A. Lendlein,et al.  CD14+ CD163+ IL-10+ monocytes/macrophages: Pro-angiogenic and non pro-inflammatory isolation, enrichment and long-term secretion profile. , 2010, Clinical hemorheology and microcirculation.